Background HPV-based screen and treat is the recommended approach for cervical cancer screening in low-resource settings, but quite low specificity of human papillomavirus (HPV) testing, particularly in women living with HIV, leads to overtreatment. We evaluated whether HPV type restriction and more stringent cutoffs on Xpert HPV optimise performance characteristics of this assay for screen and treat.
Introduction
Cervical cancer screening programmes have been ineffect ive in reducing incidence and mortality of cervical cancer in low-income and middle-income countries (LMICs). 1 Failure of screening programmes is largely due to the substantial attrition that occurs over the multistep process required by the traditional model of screening. In addi tion, a lack of resources, including insufficient colposcopy, cytology, and pathology services, introduces delays and bottlenecks that result in inefficient and ineffective programmes. [2] [3] [4] Historically, cervical cytology has been the standard screening test, and, in countries with a robust health-care infrastructure that can support this resource-intensive screening modality, the cumulative incidence of cervical cancer has been substantially reduced. 5 However, this approach has not been successfully implemented in many LMICs and WHO recommends against cytology as a screening modality for countries without pre-existing cytology-based programmes. 6 Since the early 1990s, several investigators have evaluated altern ative screening approaches to overcome the ineffici encies and bottlenecks of the traditional multistep approach. [7] [8] [9] [10] [11] [12] In the most efficient approach, screening and treating are done at a single visit. 13 The diagnostic step involving colposcopy and histological diagnosis is circum vented. In this approach, referred to as screen and treat, specificity of the screening test takes on added salience because this parameter determines the extent of over-treatment.
With all screening and diagnostic tests, there is an inevitable trade-off between sensitivity and specificity. Specificity can be improved if reductions in sensitivity can be tolerated. Assays to detect human papillomavirus (HPV) DNA have high sensitivity, hence their utility for primary screening in high-resource settings. 14, 15 Their high sensitivity also increases their utility in LMICs where screening intervals are infrequent. For the screenand-treat approach, HPV tests need to be run at the point of care to optimise participant retention. In addition, since a positive result flags a screening participant for immediate treatment, concerns have been raised about the quite low specificity of HPV DNA testing (particularly in high-risk groups such as HIV-positive women), 16, 17 the resources needed to treat large numbers of women, and risks of morbidity associated with treatment.
Xpert HPV is a WHO prequalified test that can be run as a point-of-care test, making single-visit, HPV-based screen and treat a viable reality. [18] [19] [20] [21] [22] [23] In this Article, we report results of a clinical study in South Africa to evaluate whether Xpert HPV can be optimised by selecting only some high-risk HPV types and changing cutoffs on the assay to improve specificity without producing major reductions in sensitivity in both HIVnegative and HIV-positive women.
Methods

Study design and participants
We did a diagnostic accuracy study of HIV-negative and HIV-positive women, aged 30-65 years, recruited at two sites in Cape Town, South Africa. At a primary-care facility (Khayelitsha Site B Day Hospital, Western Cape Department of Health facility) we recruited women through community outreach, considered to be representative of healthy women seeking routine screening. At a referral colposcopy clinic (Groote Schuur Hospital, tertiary hospital of the University of Cape Town) we recruited women referred to colposcopy because of abnormal cytology results obtained as part of existing screening services in the region. Inclusion criteria were: no history of any anogenital cancer; no history of treatment for cervical dysplasia; no hysterectomy; and no current pregnancy. All women provided written informed consent. The study protocol was approved by the institutional review boards of Columbia University
Research in context
Evidence before this study The success of organised cervical cancer screening with cytology in high-resource settings has not been replicated in low-resource settings. Unacceptable global disparities in cervical cancer incidence and mortality persist because of failures of organised cervical cancer screening in low-income and middle-income countries (LMICs). We searched PubMed using the search terms "cervical cancer screening", "human papillomavirus", "human immunodeficiency virus", "low resource settings", "low and middle income countries", and "screen and treat". The search included studies from database inception to Feb 1, 2019, with no language restrictions. Over the past decade a new approach to screening has been evaluated and found to be safe and effective in clinical trials in India and South Africa. This new approach is called screen and treat and is most effective if screening is first done with human papillomavirus (HPV) testing. WHO recommends HPV-based screen and treat as the preferred approach to screening in LMICs. Some providers have been reluctant to implement HPV-based screen-and-treat programmes in settings with a high HIV prevalence. This reluctance is caused by the high prevalence of HPV infection among women who live with HIV, which, in the screen-and-treat approach, leads to overtreatment.
Added value of this study
Our study investigated a method of adapting an HPV assay to improve its specificity to reduce over-treatment with HPV-based screen and treat in LMICs with high HIV prevalence. We found that by restricting the HPV assay to channels that identify a selected subset of high-risk HPV types and setting more stringent cutoffs to define the proportion of screen-positive results, specificity could be substantially improved without major reductions in sensitivity, for both HIV-positive and HIV-negative women. These adaptations do not require new engineering of the test. Instead, our approach uses existing output from the assay that can be incorporated into calculators at the provider end. This result means that decision making about the desired performance characteristics of a round of screening can be made by programme implementers. In selecting optimal cutoffs on the assay, programme implementers could weigh resource availability and community preferences.
Implications of all the available evidence
Our adaptations to the HPV assay reduce over-treatment associated with screen and treat even for women living with HIV. The assay can be run at the point of care making singlevisit, HPV-based screen and treat an optimal approach for cervical cancer screening for LMIC, including settings with a high prevalence of HIV.
(New York, NY, USA) and the University of Cape Town (Cape Town, South Africa).
Procedures
All women had a pelvic examination done by one of the study physicians, during which two cervical samples were obtained, each collected using an extended tip plastic spatula with endocervical cytobrush (Medscand, Berlin, Germany). The samples were placed in separate 20-mL vials of PreservCyt (Hologic, Bedford, MA, USA). This examination was followed by colposcopy with cervical biopsies of any abnormal-appearing areas of the cervix. If a woman had no visible lesions on the cervix, an endocervical curettage was done. A loop electro surgical excision procedure was done if clinically indicated. Women recruited at the primary-care facility were sched uled for follow-up 6 weeks after enrolment. Those with positive HPV test results or cervical intraepithelial neoplasia grade 1 on baseline histology were seen for two subsequent colposcopies to rule out missed disease. If any lesion was seen, it was biopsied or loop electrosurgical excision was done. If no lesion was seen, a random biopsy was obtained from the 12 o'clock position. After initial pathology review in Cape Town for clinical management, all histology slides were shipped to Columbia University and rereviewed. Results discordant with initial reads were reviewed by a third gynaecological pathologist as the tie-breaker for the final endpoint determination.
Xpert HPV (Cepheid, Sunnyvale, CA, USA) is a realtime polymerase chain reaction (PCR) assay that detects 14 high-risk HPV types in five fluorescent channels: HPV type 16; HPV types 18 or 45 (or both); HPV types 31, 33, 35, 52, or 58 (or more than one of these types); HPV types 51 or 59 (or both); and HPV types 39, 56, 66, or 68 (or more than one of these types). Output from the assay includes a cycle threshold value from each of these five channels. Cycle threshold values have been determ ined by the manufacturers to define a positive result for each channel (cutoff of 40 for the HPV type 16 and the HPV 18 and 45 channels and of 38 for all other channels). With PCR assays, a high cycle threshold value means a low viral load (many cycles needed to become positive) and a low cycle threshold value means a high viral load (few cycles needed to become positive). Additionally, a sample adequacy control detects whether the sample contains human DNA in a sixth channel.
Clinician-collected cervical samples were tested with Xpert HPV. A four-module GeneXpert machine (Cepheid, Sunnyvale, CA) was installed at the primary care site in Khayelitsha and a community health worker, with no prior laboratory experience, was trained in running the test. Samples collected from women recruited at the primary care site were run as soon as possible after collection and results reported to participants. Samples collected from women recruited at the colposcopy clinic were transported to the site the next day and run on the same machine. The test requires 1 mL of sample and residual material was stored.
The outcomes of the study were sensitivity, specificity, positive predictive value (PPV), negative pre dictive value (NPV), and proportion of screen-positive results of Xpert HPV for the detection of cervical intraepithelial neoplasia grade 2 or worse and grade 3 or worse in HIVpositive and HIV-negative women using all five or three selected HPV-type channels and the manufacturer's cycle threshold cutoffs. We also assessed the effect of varying cycle threshold cutoffs on sensitivity, specificity, positive predictive value (PPV), negative pre dictive value (NPV), and proportion of screen-positive results for the detection of detect cervical intraepithelial neoplasia grade 2 or worse and grade 3 or worse in HIV-positive and HIV-negative women. 
Statistical analysis
A sample size of 600 women from the screening population and 400 women from the referral population (equal numbers of HIV-positive and HIV-negative women in each group) was selected a priori on the basis of estimates of sensitivity, specificity, and prevalence of cervical intraepithelial neoplasia grade 2 or worse in the four groups, with the aim of including a large enough number of women with cervical cancer precursor lesions and of attaining a precision of plus or minus 6% around the sensitivity estimates and plus or minus 5% around the specificity estimates stratified by HIV status. The referral population was included in order to generate sufficient numbers of women with precursor lesions required for sensitivity calculations (enrichment principle). For calculation of sensitivity, cervical intraepithelial neoplasia grade 2 or worse or grade 3 or worse based on adju dicated pathology were defined as true disease. Women recruited from both sites were included for calculations of sensitivity. For calculation of specificity, the absence of cervical intraepithelial neoplasia grade 2 or worse included adjudicated pathology diagnosis of within normal limits or cervical intraepithelial neoplasia grade 1, and the absence of cervical intraepithelial neoplasia grade 3 or worse included diagnosis of within normal limits, cervical intraepithelial neoplasia grade 1, or cervical intra epithelial neoplasia grade 2. Only women recruited from the primary care site were included in specificity, PPV, and NPV calculations to ensure estimates reflected women in a screening setting. 95% CIs around sensitivity, specificity, PPV, and NPV were calculated using the binomial method.
To investigate effects of changing cutoffs on the performance of Xpert, logistic regression models predicting presence or absence of cervical intraepithelial neoplasia grade 2 or worse or of cervical intraepithelial neoplasia grade 3 or worse on the basis of channelspecific reverse cycle threshold values were run in HIVnegative and HIV-positive women separately. If the cycle threshold values were considered positive by the assay, we defined the reverse cycle threshold value equal to 45 minus the observed cycle threshold value (45 was chosen as it was the highest cycle threshold value observed in the data). If the cycle threshold values were considered negative by the assay, we defined the reverse cycle threshold value equal to zero. The reverse cycle threshold value from each channel was considered a separate variable. The final logistic regression models included reverse cycle threshold values from channels that, when included together in multivariable models, were significantly associated with disease (p<0·05).
From the final logistic regression models, receiver opera ting characteristic (ROC) curves were generated and the area under the curve (AUC) calculated. Specificity estimates were derived from the ROC curves at sensitivity levels ranging between 85% and 65%. PPV, NPV, and the proportion of screen-positive results were calculated applying the observed prevalence of cervical intraepithelial neoplasia grade 2 or worse or of cervical intraepithel ial neoplasia grade 3 or worse in the screening population and the sensitivity and specificity estimates were derived from the ROC curves (see appendix). SEs for these parameters were calculated using the delta method. Statistical analyses were done using SAS version 9.4. 
Sensitivity
Role of the funding source
The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all of the data and the final responsibility to submit for publication.
Results
Between Feb 16, 2015, and May 16, 2016, we recruited 586 HIV-negative women (382 from the primary care facility and 204 from the colposcopy clinic) and 535 HIVpositive women (333 from the primary care facility and 202 from the colposcopy clinic). We enrolled slightly higher numbers of participants than the prespecified sample size because enrolment proceeded more rapidly than planned. The prevalence of cervical intraepithelial neo plasia grade 2 or worse in the screening population was lower in HIV-negative (5·3%, 95% CI 3·0-7·6) than in HIV-positive women (17·0%, 12·9-21·0), as was the prevalence of cervical intraepithelial neoplasia grade 3 or worse (3·2%, 1·4-4·9, in HIV-positive women and 8·5%, 5·5-11·5 in HIV-negative women). Odds of cervical intra epithelial neoplasia grade 2 or worse (odds ratio [OR] 0·304, 0·177-0·522) and grade 3 or worse (0·398, 0·197-0·802) were lower in HIV-negative compared with HIV-positive women, adjusting for age. Most HIVpositive women recruited at the primary care site (266 [80%] of 333) were on antiretroviral therapy and the median CD4 counts were 455 cells per µL (IQR 300-630). Prevalence of HPV DNA was also lower in HIV-negative (16·2%, 95% CI 12·4-19·9) than HIV-positive women (48·4%, 43·4-54·2) after adjusting for age (OR 0·223, 0·156-0·317; table 1). Sensitivity of HPV DNA testing to detect cervical intraepithelial neoplasia grade 2 or worse using all five channels and the manufacturer's cycle threshold cutoffs was high in HIV-negative and HIV-positive women (table 2). Restricting to the three channels detecting HPV types 16, 18, 45, 31, 33, 35, 52, and 58 and using manufacturer's cutoffs, sensitivity was only modestly reduced in both HIV-negative and HIV-positive women. Corresponding specificities, PPV, NVP, and proportion of screen-positive results and results for cervical intraepithelial neoplasia grade 3 or worse are shown in table 2.
In multivariable analysis, only reverse cycle threshold values for the first three channels were significantly predictive of cervical intraepithelial neoplasia grade 2 or worse. For HIV-negative women, the adjusted OR (aOR) was 1·33 (95% CI 1·25-1·41) with the HPV type 16 channel, 1·17 (1·09-1·25) with the HPV types 18 and 45 channel, and 1·27 (1·21-1·33) with the HPV type 31, 33, 35, 52, and 58 channel. For HIV-positive women, the aOR was 1·19 (1·14-1·25) with the HPV type 16 channel, 1·09 (1·04-1·13) with the HPV types 18 and 45 channel, and 1·17 (1·13-1·21) for the HPV types 31, 33, 35, 52, and 58 channel.
Results for cervical intraepithelial neoplasia grade 3 or worse for HIV-negative women were similar to those for cervical intraepithelial neoplasia grade 2 or worse. The aOR was 1·35 (95% CI: 1·26-1·44) with the HPV type 16 channel, 1·17 (95% CI: 1·08-1·27) with the HPV types 18 and 45 channel, and 1·27 (95% CI: 1·21-1·35) with the HPV types 31, 33, 35, 52, and 58 channel. For HIV-positive women, only the HPV type 16 channel (1·16, 1·11-1·21) and the HPV types 31, 33, 35, 52, and 58 channel (aOR 1·16, 1·12-1·20) were significant predictors of cervical intraepithelial neoplasia grade 3 or worse.
In HIV-negative women, the AUC for cervical intraepithelial neoplasia grade 3 or worse was slightly higher (0·928) than for cervical intraepithelial neoplasia grade 2 or worse as the endpoint (0·907). For HIV-positive women, the AUC was the same regardless of endpoint (0·868) and was slightly lower than in HIV-negative women. Specificity was more variable and lower in HIVpositive women than in HIV-negative women (figure 1).
Sensitivity was allowed to range between 65% and 85% and the corresponding specificities derived from the ROC curves from the multivariable logistic regression are shown in table 3. For example, if sensitivity for cervical intraepithelial neoplasia grade 2 or worse is allowed to decline to 80%, by applying more stringent cutoffs to the three channels detecting HPV types 16, 18, 45, 31, 33, 35, 52 , and 58, specificity increases to 94·1% in HIV-negative women and 83·2% in HIV-positive women. Logistic regression models predict disease based on the joint predictive capability of the cycle threshold values on three channels. For women who are positive on more than one channel, the cycle threshold value defining a screen-positive result depends on the cycle threshold values in other channels and would need to be calculated for each woman individually on the basis of the observed cycle threshold values across the three channels. For illustrative purposes, for women positive on only one channel, we back-calculated the cycle threshold value required to attain a sensitivity of 65-85% for detection of cervical intra epithelial neoplasia grade 2 or worse (figure 2). For example, cycle threshold values on the HPV type 16 channel need to be 35·9 or less for HIV-negative women to be defined as positive with a sensitivity of 80% or more (specificity ≤94·1%) or 37·8 or less with a sensitivity of 85% or more (specificity ≤91·3%).
Discussion
We did a large and rigorous clinical study in Cape Town, South Africa, to evaluate a novel approach to adapting an existing approved HPV test to increase its suitability for screen and treat. Both type restriction and changing cutoffs to define a positive result led to substantial improvements in specificity, PPV, and proportion of screen-positive results, while producing only minor reduct ions in sensitivity. Benefits were particularly noteworthy for HIVpositive women, among whom the prevalence of HPV infection is high.
HPV assays have been designed to detect the 14 highrisk HPV genotypes associated with cervical cancer and its precursor lesions. During assay development, cutoff values are identified that allow tests to achieve sensitivity and specificity at predefined benchmarks. [24] [25] [26] However, performance characteristics appropriate for an HPV assay used for primary screening in the USA and Europe are different to those desired for a test used for screen and treat in LMICs. With the screen-and-treat approach, some clinicians believe that HPV results should serve as the basis for determining whether women get treatment, whereas others prefer that an additional triage step such 
Cervical intraepithelial neoplasia grade 3 or worse
Sensitivity in HIV-negative women
Sensitivity in HIV-positive women a visual inspection with acetic acid (VIA) be performed before treatment. In large part this controversy is driven by the quite low specificity of currently available HPV assays. We found that restricting Xpert HPV to eight HPV genotypes (HPV 16, 18, 45, 31, 33, 35, 52, 58) resulted in a negligible effect on sensitivity, but led to improvements in specificity, in both HIV-negative and HIV-positive women. For HIV-negative women, the improvement in specificity from 86·9% to 89·7% obtained by type restriction alone makes Xpert HPV suitable for screen and treat with out any further modifications. However, for HIV-positive women, although type restriction improved performance characteristics, further improvements would be desirable.
Our study shows that making more stringent cutoffs on the three channels on Xpert HPV that detect HPV types 16, 18, 45, 31, 33, 35, 52 , and 58 was an effective way to achieve an optimal balance between sensitivity and specificity. Since Xpert HPV is a PCR assay, we can use the cycle threshold value as a rough approximation of the quantity of HPV DNA present or viral load. For HIVnegative women, if we allow sensitivity for cervical intraepithelial neoplasia grade 2 or worse to decline to 80%, specificity is 94·1%. In our study population, this means that 9·8% of women would screen positive with a PPV for cervical intraepithelial neoplasia grade 2 or worse of 43·1%. These are highly attractive parameters for an effective screen-and-treat programme.
It is for HIV-positive women that the benefits of shifting to more stringent cutoffs are most notable. For HIV-positive women, we observed that if we allow sensitivity for cervical intraepithelial neoplasia grade 2 or worse to decline to 80%, specificity improves to 83·2%. At this sensitivity-to-specificity balance, 27·5% of women would now be screen-positive with a PPV of 49·4%. For the test as originally configured, 48·8% of HIV-positive women would be screen-positive and the PPV would be 31·7%. Our adaptation is a considerable improvement and makes screen and treat a good choice for this population.
An advantage of Xpert HPV is that the cycle threshold values of each channel are part of standard output. Thus, it is not necessary to undertake any new engineering of the test to change the cutoffs. A calculator at the output level of the test can be used to classify women. This calculator would be programmed with the logistic regression parameters and would input the cycle threshold values from an individual and then output the classification as screen-positive or screen-negative. The features of this assay allow decision making about performance characteristics of the screening test to be shifted to programme implementers. To our knowledge, Xpert HPV is the only PCR-based and field-friendly assay that has been clinically validated. More cheap and validated assays with point-of-care applicability would be welcome. Assays with a quantifiable signal output and separation of HPV types would have the additional advantage of flexibility that could be used in the way we propose here.
The lack of availability, until now, of a robust, point-ofcare HPV assay is the major reason for which several screen-and-treat programmes have had to rely on VIA as the primary screening test. VIA is appealing for many reasons, not the least of which is its low cost. Unfortunately, performance characteristics of VIA as a screening test are poor. Clinical trials in South Africa and India have found substantially better outcomes with HPV-based screen-and-treat. [7] [8] [9] Although costs of HPV assays are still quite high, rigorous cost-effectiveness analyses have confirmed the affordability of HPV-based screen and treat given the savings accrued by simplification of the screening cascade and reduced number of visits. 13, 27 The impetus and infrastructure built to support VIA-based screen and treat is ideally positioned to now incorporate HPV testing.
In selecting optimal cutoffs on the assay, programme implementers could weigh resource availability and community preferences. For example, if there are insufficient clinicians to treat the 27·5% of HIV-positive women who would require treatment if sensitivity is set at 80%, cutoffs could be shifted to a lower sensitivity resulting in a smaller percentage of women in need of treatment. Some might question the wisdom of reducing sensitivity to 80%, or even lower, because of resource limitations. Current guidance generally advises that a candidate HPV test should have a sensitivity for cervical intraepithelial neoplasia grade 2 or worse of no less than 90% of the sensitivity of hybrid capture 2 (HC2) in women aged 30 years and older. 28 At the time these recommendations were made (in 2009) the pooled sensitivity of HC2 was 97·9%. 28 2012 pooled analyses have slightly lower estimates. 14 However, it is important to recognise that cytology has a much lower sensitivity than HPV testing. For example, the USA-based ATHENA trial found the sensitivity of liquid-based cytology for cervical intraepithelial neoplasia grade 3 or worse to be only 53·3%. 29 Despite its much lower sensi tivity, cytology is still considered an acceptable screen ing test in several countries. 6 In addition, since our approach excludes women with lower HPV viral loads, the com promises in sensitivity might be less than reported here. Prospective studies are needed to evaluate this possibility. Preferences of the clinical community could also be taken into account. For example, for settings where over-treatment is less tolerated, cutoffs that ensure high PPV could be chosen. By contrast, where few alternative treatment options are available and women are likely to be infrequently screened, higher sensitivity could be selected and more over-treatment tolerated.
Our study has several limitations. For reasons of efficiency, we recruited women from both a screening population and a referral population to attain sufficient numbers with the desired clinical endpoints. As such, this casemix might not be representative of disease detected in a screening population. Recruiting only from a screen ing population is prohibitively expensive. Our approach of enriching the study population from a referral popula tion in order to attain the number of cases needed for sensitivity calculations has also been applied in the VALGENT HPV test validation protocol. 26 In addition, our endpoint definition was rigorous with only confirmed cases of cervical intraepithelial neoplasia grade 2 or worse or grade 3 or worse on histology included. Our study population was recruited in a single geographic area and therefore the findings cannot be generalised to other geographic regions.
Screen and treat has many advantages in the setting of our study, where most women have limited access to health care, most health-care services are curative rather than preventive, and human and financial resources are insufficient. A major advantage is improved coverage of the target population and reduction in attrition. Other advantages include improved test performance of molecular tests compared with cytology, the ease of applying the test, and ease of access for women living in impoverished circumstances as the activity takes place in clinics in the community. The lack of need for laboratory-based services, coordination between clinics and labor atories, or reliable transport between them are further advantages that make the HPV-based screen and treat particularly advantageous for LMIC. Our approach allows screen-and-treat programmes to adjust to resource constraints, local disease prevalence, and clini cal values and preferences. Implementation studies are urgently needed.
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